Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
about
Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trialsα7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumA practical algorithm for managing Alzheimer's disease: what, when, and why?Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific RegionProgressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severitySafety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's diseaseCurrent and emerging drug treatment options for Alzheimer's disease: a systematic review.Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.Acetylcholinesterase inhibitors: pharmacology and toxicology.Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.Five skills psychiatrists should have in order to provide patients with optimal ethical care.Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease.Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled TrialAlzheimer's disease: diagnosis and treatment across the spectrum of disease severityDonepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot studyImaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies.Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease.Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scoresLanguage impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.Somatic comorbidities and Alzheimer's disease treatment.Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotilityRepeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers.Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment StrategyOral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers.Print advertisements for Alzheimer's disease drugs: informational and transformational features.Drug delivery strategies for Alzheimer's disease treatment.A 10-year perspective on donepezil.High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease.Advances in the treatment of cognitive impairment in Parkinson's disease.
P2860
Q26851862-77A99254-AA63-4287-AF67-D7B7672B917AQ26852967-9681DE40-CC25-4129-BAE8-2035D9AC6CFAQ26859831-CC2AD1D7-7592-4801-9E4E-F7344FCD987BQ28067006-B5A473AD-C3C4-4E9C-B4CB-C2944F8A2452Q30998627-D9D62991-C8E7-404F-B88B-6BB3017D13A3Q33165801-7CD7748B-33DC-49D7-B0AA-C9EE4DD40D21Q33586027-654433E0-AFC9-48EF-8A4E-3789447AA25EQ33746082-DCC6E5C4-F10C-46F8-B7FD-4EF67FC2E922Q33911859-E6F935EF-E838-4779-8045-FC40FFFF5CC9Q34222721-8AE817D0-3381-445D-95C5-7F060CF30E4BQ34297733-81B388C1-9183-4BAE-A101-57D37146A53BQ34381860-473F3DC0-3310-4DB5-8736-2EB34A3A9231Q34463351-A29284AB-9E0D-48B7-846B-A8503C0F3503Q34521949-F7C6E8EB-1115-43E7-B5C5-ABDEBB8D7082Q34549155-95E6A4E4-9DC8-4231-A9F1-B3D533749353Q34762064-E0AE4A02-635D-4DCF-B30C-91C24566EDF6Q34779702-F13B83AB-F5AE-4E1A-8402-6866EB865AB6Q35606762-BCDF3D15-614F-4194-8DB1-18913E4919C6Q35663934-9F7918E4-2A9B-4FFA-A44B-3A90E33F72D8Q35860723-94BB8FDE-CC20-46BB-B6CC-47BC787F60BBQ35966108-B6EB5021-FB8D-47B5-90ED-D46E10346CC3Q36124416-AD447F89-FE79-469B-A1D6-79C4C0C79A83Q36384458-51B540B6-EA61-4839-B603-C7909D1EF972Q36863807-8AFAB499-006F-45C6-88F9-78463047A4F5Q37084847-8EE13AAA-FE80-4097-944A-8F4D32AA5338Q37199794-73D14B0C-0C6A-4530-9DCE-561D1CF4146EQ37282357-BEC97896-D76B-4DCA-9167-D73CA7E59065Q37337891-EC533390-0A93-4AB5-A1A8-11F60D3EED9DQ37347844-B325A40D-91F6-4F71-8E9F-7B9871FF84C3Q37553489-7FED11D0-99A6-4315-AD50-E76CFC9CFE46Q37620814-49EFE865-64BB-4DB1-AE1A-C393B6737869Q37659423-A73FD701-99DE-4E73-A463-1BD5E79087ABQ37851509-CCB1673F-2320-4152-8FCF-DC585620AEDAQ38073793-75682EE9-B39B-4B8F-A52F-B4A1E41FB376Q38086651-2D9D012F-8CE0-4A3B-8820-F20E5D8FB35AQ38127470-B4887F69-F3B9-4444-B5E4-E07ADE339E84Q38150708-27995795-1B9D-4D18-A190-2EC5D30A2AA1Q38208461-BFE00A6C-CA3A-487D-882D-FF4FC3B9F69FQ38489147-3F1B2E3A-F443-4368-B00B-A472FBF61DF7Q38571668-0E1D5661-65FA-4197-9F52-83B17D5703E9
P2860
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effectiveness and tolerability ...... andomized, double-blind study.
@ast
Effectiveness and tolerability ...... andomized, double-blind study.
@en
Effectiveness and tolerability ...... andomized, double-blind study.
@nl
type
label
Effectiveness and tolerability ...... andomized, double-blind study.
@ast
Effectiveness and tolerability ...... andomized, double-blind study.
@en
Effectiveness and tolerability ...... andomized, double-blind study.
@nl
prefLabel
Effectiveness and tolerability ...... andomized, double-blind study.
@ast
Effectiveness and tolerability ...... andomized, double-blind study.
@en
Effectiveness and tolerability ...... andomized, double-blind study.
@nl
P2093
P2860
P1476
Effectiveness and tolerability ...... andomized, double-blind study.
@en
P2093
Andrew Satlin
Elimor Brand-Schieber
Jane Yardley
Margaret L Moline
Martin R Farlow
Pierre N Tariot
Stephen Salloway
Timothy Hsu
P2860
P304
P356
10.1016/J.CLINTHERA.2010.06.019
P577
2010-07-01T00:00:00Z